中晚期胃癌术中腹腔内植入氟尿嘧啶缓释剂37例

An Analysis of Intraperitoneal Interstitialimplant with Sustained-Release 5-Fluorouracil during Operation for 37 Cases with Advanced Gastric Cancer

[目的]评价中晚期胃癌术中腹腔内植入氟尿嘧啶缓释剂的疗效。[方法]112例Ⅲb期胃癌分三组:治疗组1为37例,术中即时低渗温热腹腔化疗联合腹腔内植入氟尿嘧啶缓释剂,治疗组2为38例,术中即时低渗温热腹腔化疗联合术后早期腹腔化疗,对照组为37例。[结果]三组病例腹腔化疗的并发症比较均无显著性差异,治疗组1消化道反应的发生率(2.70%)低于治疗组2(21.05%,P<0.05)。三组病例1年生存率无显著性差异,治疗组1的2年生存率(70.27%)明显高于对照组(40.54%,P<0.05),但与治疗组2(55.26%)比较无显著性差异。[结论]中晚期胃癌术中腹腔内植入氟尿嘧啶缓释剂是一种有效且毒副反应轻的腹腔化疗方法。

[Purpose] To assess the effect of intraperitoneal interstitial implant with sustained-release 5-fluorouracil during operation for advanced gastric cancer. [Methods ] One hundred and twelve cases with gastric cancer stage mb were divided into 3 groups： treatment group 1 （n=37）, combined intraoperative hypotonic peritoneal chemo-hyperthermia and implant with sustained-release 5-fluorouracil; treatment group 2 （n=38）, intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperatively intraperitoneal chemothetapy; and control group （n= 37）, peritoneal lavage with distilled water alone. [Results ] There was no significantly difference in complication and 1-year survival rate among three groups. Digestive tract toxicity in group 1 （2.7%） was lower than that in group 2 （21.05%）, （P〈0.05）. The 2-year survival rate of group 1 （70.27%） was higher than that in control group （40.54%）, （P〈0.05）. There was no significant difference between group 1 （2.7%） and 2 group （55.26%）. [Conclusion] Intraperitoneal interstitial implant with sustained-release 5-fluorouracil during operation acts as an effective intraperitoneal chemotherapy with mild side effects for advance gastric cancer.